Physician profile
Robert Silverbrook
NPI 1083665558
$2,228.87
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,536 · 2020: $322 · 2021: $86.07 · 2022: $286.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $401.61 | 2019-2022 | |
| Novo Nordisk INC | $297.48 | 2019-2022 | |
| Abbvie INC. | $187.76 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.56 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $122.55 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $106.30 | 2019-2021 | |
| Pfizer INC. | $99.59 | 2019-2020 | |
| Allergan, INC. | $90.10 | 2019-2020 | |
| Glaxosmithkline, LLC. | $84.79 | 2019-2022 | |
| Lilly USA, LLC | $65.35 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $56.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $47.72 | 2019 | |
| Astellas Pharma US INC | $42.61 | 2019-2020 | |
| Amgen INC. | $41.63 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $41.62 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $37.23 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.22 | 2022 | |
| Genentech USA, INC. | $31.28 | 2019-2020 | |
| Amarin Pharma, INC. | $29.15 | 2019 | |
| Scilex Pharmaceuticals INC. | $28.57 | 2019 | |
| Sanofi Pasteur INC. | $28.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $24.19 | 2019 | |
| Organogenesis INC. | $24.08 | 2022 | |
| Abbott Laboratories | $22.69 | 2020 | |
| Daiichi Sankyo INC. | $21.13 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.96 | 2019 | |
| Eisai INC. | $14.14 | 2019 | |
| Esperion Therapeutics, INC. | $14.03 | 2020 | |
| Currax Pharmaceuticals LLC | $13.71 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.62 | 2019 | |
| Circassia INC. | $13.42 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.50 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Silverbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.